Galectin Therapeutics Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA
Pharmaceutical Investing Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain MetastasisÂ
SOURCE ROCK ROYALTIES ANNOUNCES FOURTH QUARTER & YEAR-END 2024 RESULTS INCLUDING RECORD ANNUAL FUNDS FROM OPERATIONS
